$Amedica(AMDA)$ "We appreciate the cooperation from our investment partners and believe these amended warrant terms are mutually beneficial for the warrant holders, Amedica, and our shareholders," said Ty Lombardi, Principal Accounting Officer. "These amendments should minimize the uncertainty of our capital structure associated with the prior terms of the Series A and Series C warrants."

The amended agreement terms fix the exercise price of each of the Series A and Series C warrants at the current exercise prices, and caps the number of shares issuable by the Company upon exercise of the Series C warrants at 16.4 million, as outlined in the Form 8-K filed on December 14, 2015. As a result of the amended terms, the exercise price of Series A warrants is no longer subject to further downward adjustment pursuant to an automatic exercise of the Series C warrants.

Additionally, the Series A warrants are now exercisable as of December 11, 2015, the date of the amendment. The Series C warrants are no longer subject to automatic exercise but, rather, the holders of the Series C warrants can exercise their warrants at any time prior to the termination date of December 30, 2015.

The amendments also allow the Series A warrants to be exercisable on a cashless basis, provided that if the warrant holder is going to receive shares of registered common stock, the Volume Weighted Average Price (VWAP) used in the cashless calculation cannot exceed $0.15. As of December 11, 2015, the Company had registered 13.1 million shares of common stock underlying the Series A warrants for resale with the SEC. Should the holders of the Series A warrants exercise them on a cashless basis to receive all 13.1 million shares currently registered for resale, using an applicable VWAP of $0.15, the number of aggregate warrant shares available immediately after the exercise of the Series B warrants of 63.0 million would be reduced to an aggregate of 23.8 million warrant shares.